Ausência de anticorpos antilipoproteína lipase na doença de Behçet

Abstract

Objective: The recent description of anti-lipoprotein lipase antibodies (anti-LPL) associated with dislipoproteinemia led us to analyze its presence and possible association with clinical and laboratorial findings in patients with Behçet's disease. Patients and Methods: Thirty-eight consecutive patients with Behçet's disease [International Study Group for Behçet's Disease (ISGBD) criteria] were tested for the presence of anti-LPL antibodies by ELISA. Patients underwent clinical and laboratorial evaluation, including fasting lipid profile, determination of autoantibodies, and inflammatory markers (CRP, ESR) before inclusion in the study. Exclusion criteria were as follows: any conditions that affected the lipid profile. Results: Patients had a mean age of 42 ± 9 years, 68% were females, and 68% were Caucasian. Mean disease duration was 9.8 ± 7.5 years. Twenty-nine percent of the patients had a history of thrombosis. C-reactive protein levels were elevated in 31% of the patients, and ESR was increased in 31% of the patients, with mean levels of 5.95 ± 10.3 mcg/mL and 14.5 ± 13.2 mm/1 st hour, respectively. Approximately 47% of the patients were taking prednisone, with a mean dose of 7.6 ± 10.8 mg/day. As for NCEP/ATPIII cardiovascular risk levels, cholesterol levels were elevated in 26% of the patients, triglycerides in 18%, low HDL in 15%, and elevated LDL in 25% of the patients with Behçet's disease. Mean total cholesterol levels were 198 ± 48 mg/dL, triglycerides 121 ± 61 mg/dL, HDL 52.4 ± 14.7 mg/dL, and LDL 119 ± 35 mf/dL. IgG anti-LPL antibodies were detected in 0/30 patients with Behçet's disease. Conclusion: The data presented here indicates the lack of correlation among inflammation, immune response, and dislipoproteinemia in patients with Behçet's disease and suggests that other mechanisms are associated with the dyslipedemia seen in those patients.